Product image of Lenalidomide Mercury Pharmaceuticals Ltd. (Lenalidomide) supplied by GNH India

Lenalidomide Mercury Pharmaceuticals Ltd.

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Mercury Pharmaceuticals Ltd. (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Mercury Pharmaceuticals Ltd., is an immunomodulatory drug (IMiD) presented as a tablet for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH India supplies Lenalidomide Mercury Pharmaceuticals Ltd. as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Mercury Pharmaceuticals Ltd.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic bone‑marrow clones.

  • Multiple myeloma: improves response rates and prolongs progression‑free survival.
  • Myelodysplastic syndromes with del(5q): reduces transfusion dependence and improves peripheral blood counts.
  • Mantle cell lymphoma: induces remission in relapsed or refractory disease.

How It Works

  • Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering substrate specificity and leading to degradation of transcription factors Ikaros and Aiolos. This results in enhanced T‑cell and natural killer‑cell activity, inhibition of angiogenesis, and direct induction of apoptosis in malignant plasma cells and dysplastic clones.

Side Effects

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Neutropenia: reduced white blood cell count.
  • Thrombocytopenia: lowered platelet levels.
  • Fatigue: persistent tiredness.
  • Nausea: upset stomach and vomiting.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in veins.
  • Severe neutropenia or thrombocytopenia: risk of infection or bleeding.
  • Secondary primary malignancies: emergence of new cancers.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient risk factors and monitor for complications.

  • Monitor blood counts: perform regular CBCs to detect cytopenias.
  • Assess thrombotic risk: consider prophylactic anticoagulation for high‑risk patients.
  • Avoid pregnancy: teratogenic; enforce effective contraception.
  • Adjust dose in renal impairment: follow prescribing guidelines for reduced clearance.
  • Store at ambient temperature: keep below 25°C, protect from moisture and light.

Avoid Interactions

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): markedly reduce lenalidomide exposure.
  • Anticoagulants (e.g., warfarin): increase bleeding risk.
  • Live vaccines: heightened infection risk due to immunomodulation.
  • Immunosuppressants: may diminish therapeutic efficacy.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (e.g., ketoconazole): raise plasma concentrations.
  • NSAIDs: elevate risk of thrombocytopenia.
  • CYP2C19 inhibitors: potential impact on metabolism.
  • P‑gp inhibitors: may increase systemic exposure.

Frequently Asked Questions

Lenalidomide is indicated for adult patients with multiple myeloma, myelodysplastic syndromes that have a deletion of chromosome 5q (del(5q)), and mantle cell lymphoma, particularly in relapsed or refractory settings.

Lenalidomide binds to the cereblon protein within the CRL4‑CRBN ubiquitin ligase complex, leading to degradation of specific transcription factors. This enhances immune cell activity, blocks new blood‑vessel formation, and directly triggers apoptosis of malignant cells.

The dose of Lenalidomide is individualized by the prescribing clinician based on the specific indication, patient characteristics, and renal function. Patients should follow the exact regimen provided by their healthcare professional.

Lenalidomide is classified as Pregnancy Category X because it can cause fetal harm. It is contraindicated in pregnancy, and effective contraception is required. Breastfeeding is not recommended while taking the medication.

To request Lenalidomide, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class and differs from proteasome inhibitors or monoclonal antibodies by primarily enhancing immune surveillance and inducing tumor‑cell apoptosis. It is often used in combination regimens and may be preferred when patients require an oral therapy with a distinct mechanism of action.

Lenalidomide tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Do not store in areas of high humidity or direct sunlight.

Lenalidomide is taken orally, usually once daily, with or without food, as directed by the treating physician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include severe neutropenia or thrombocytopenia, which can lead to infection or bleeding, venous thromboembolism, secondary primary malignancies, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome.

Lenalidomide should not be used by patients who are pregnant, planning to become pregnant, or who cannot use effective contraception. It is also contraindicated in individuals with known hypersensitivity to lenalidomide or its excipients.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT